KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Assets (2016 - 2025)

Historic Return on Assets for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to 0.2%.

  • Acadia Pharmaceuticals' Return on Assets rose 700.0% to 0.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.2%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 0.23% for FY2024, which is 3300.0% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Return on Assets stood at 0.2% for Q3 2025, which was up 700.0% from 0.19% recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Return on Assets high stood at 0.21% for Q4 2024, and its period low was 0.36% during Q4 2022.
  • Over the past 5 years, Acadia Pharmaceuticals' median Return on Assets value was 0.23% (recorded in 2023), while the average stood at 0.12%.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Return on Assets tumbled by -1300bps in 2022, and later soared by 3700bps in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Return on Assets (Quarter) stood at 0.24% in 2021, then plummeted by -53bps to 0.36% in 2022, then surged by 76bps to 0.09% in 2023, then skyrocketed by 336bps to 0.21% in 2024, then decreased by -2bps to 0.2% in 2025.
  • Its Return on Assets stands at 0.2% for Q3 2025, versus 0.19% for Q2 2025 and 0.2% for Q1 2025.